HyperTiss 膀胱癌治療用膀胱内低体温療法セット

HyperTiss 膀胱癌治療用膀胱内低体温療法セット

制御された低体温療法を膀胱腔に直接投与するよう設計された先進医療システムで、化学療法に対する腫瘍の感受性を高め、再発率を低下させることにより、膀胱がん治療の治療成績を向上させる。

インフォメーション

について HyperTiss Intracavitary Hypothermia Set offers a multifactorial approach to bladder tumor management by combining chemotherapy with targeted hyperthermia in a controlled, patient-friendly delivery system. Through a specialized Three-Way Foley Silicone Catheter and advanced temperature control technology, HyperTiss ensures precise thermal and drug regulation—optimizing chemo-hyperthermia’s efficacy against cancerous tissue within the bladder while prioritizing patient safety and comfort.

System Components & Design

Three-Way Foley Silicone Catheter
  • High-Quality Silicone: Minimizes irritation to the bladder wall, promoting patient tolerance during extended intravesical therapy.
  • Multi-Port Access: Enables drug instillation, temperature monitoring, and continuous fluid exchange with minimal instrumentation.
  • Secure Fluid Pathways: Prevents leakage or accidental disconnection, providing stable infusion and drainage ports for the anticancer solution.
  • Two-Way Stopcock: Offers operator-friendly toggling between infusion, drainage, or sealed modes during the procedure.
  • Precise Temperature Regulation: Monitors and maintains fluid temperature within a 41–44°C range (±0.2°C) per physician protocol.
  • Optimized Hyperthermia Delivery: Ensures uniform heat distribution across the bladder mucosa, enhancing drug uptake.
  • Fluid Management: Simplifies infusion, drainage, or recirculation processes for delivering heated chemotherapy solutions.
  • Transparent & Latex-Free: Allows clinicians to observe fluid levels and flow conditions, supporting safe handling.
  • Flexible, Atraumatic: Minimizes mechanical stress on the bladder or the infusion line, enhancing patient safety and comfort.
  • Biocompatible Construction: Resists kinking and maintains consistent fluid passage even under repeated bending.

Therapeutic Rationale: Chemo-Hyperthermia

Synchronized Temperature & Drug Delivery
  • HypertISS: (Hypothermia might be a mis-labelling or it’s “HyperTiss” but anyway) By raising local tissue temperature to 41–44°C, the synergy between heat and chemotherapeutic solutions intensifies cancer cell death.
  • Favorable Tissue Response: Hyperthermia triggers changes in tumor vasculature, enhancing chemotherapeutic penetration and susceptibility of malignant cells to cytotoxic agents.
  • Improved Oncologic Control: Enhanced tissue drug levels plus disruption of tumor cell defense mechanisms can lower progression or relapse of bladder tumors.
  • Better Resource Allocation: Effective local therapy can lessen the need for extensive systemic treatments, cutting down cost and toxicity profiles.

Clinical Advantages & Indications

Enhancing Chemotherapy Efficacy
  • Targeted Hyperthermia: Elevates local temperature in the bladder to potentiate chemotherapeutic effects, thereby improving tumor cell kill rates.
  • Increased Drug Penetration: Heated environment encourages deeper and more consistent uptake of anticancer agents.
  • Combination of Heat & Ionized Molecule Delivery: Creates a synergy that overcomes drug resistance and fosters thorough coverage of bladder lesions.
  • Reduced Systemic Toxicity: Local administration confines drug exposure mainly to the bladder region, potentially lowering systemic side effects.
  • Outpatient/Local Anesthesia: Many procedures can be performed on a short-stay basis, optimizing hospital resources and improving patient quality of life.
  • Reliable Monitoring & Control: Comprehensive alarm systems plus real-time temperature feedback maintain high standards of safety.
  • Automatic Safety Shutdown: Mitigates risk if unexpected temperature or pressure fluctuations occur.
  • Alarm Alerts: Minimizes operator error and ensures the procedure remains within the safe therapeutic window.

関連商品